Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1985
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1989 2
1990 1
1991 2
1992 4
1993 4
1994 12
1995 7
1996 20
1997 14
1998 10
1999 23
2000 22
2001 17
2002 40
2003 31
2004 30
2005 29
2006 30
2007 36
2008 35
2009 42
2010 40
2011 67
2012 56
2013 68
2014 58
2015 63
2016 61
2017 73
2018 59
2019 64
2020 75
2021 55
2022 48
2023 53
2024 44
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

1,174 results

Results by year

Filters applied: . Clear all
Page 1
Mantle cell lymphoma-Update on molecular biology, prognostication and treatment approaches.
Silkenstedt E, Dreyling M. Silkenstedt E, et al. Hematol Oncol. 2023 Jun;41 Suppl 1:36-42. doi: 10.1002/hon.3149. Hematol Oncol. 2023. PMID: 37294961 Review.
Mantle cell lymphoma (MCL) is clinically characterized by its heterogenous behavior with courses ranging from indolent cases that do not require therapy for years to highly aggressive MCL with very limited prognosis. ...
Mantle cell lymphoma (MCL) is clinically characterized by its heterogenous behavior with courses ranging from indolent
Mantle-Cell Lymphoma.
Armitage JO, Longo DL. Armitage JO, et al. N Engl J Med. 2022 Jun 30;386(26):2495-2506. doi: 10.1056/NEJMra2202672. N Engl J Med. 2022. PMID: 35767440 Review. No abstract available.
Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.
Hill HA, Qi X, Jain P, Nomie K, Wang Y, Zhou S, Wang ML. Hill HA, et al. Blood Adv. 2020 Jul 14;4(13):2927-2938. doi: 10.1182/bloodadvances.2019001350. Blood Adv. 2020. PMID: 32598477 Free PMC article.
Mantle cell lymphoma (MCL) is an incurable rare subtype of non-Hodgkin lymphoma and is subject to relapse and therapeutic resistance. ...
Mantle cell lymphoma (MCL) is an incurable rare subtype of non-Hodgkin lymphoma and is subject to relapse and th
Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management.
Jain P, Wang M. Jain P, et al. Am J Hematol. 2019 Jun;94(6):710-725. doi: 10.1002/ajh.25487. Epub 2019 Apr 19. Am J Hematol. 2019. PMID: 30963600 Free article. Review.
Unprecedented advances in our understanding of the pathobiology, prognostication, and therapeutic options in mantle cell lymphoma (MCL) have taken place in the last few years. Heterogeneity in the clinical course of MCL-indolent vs aggressive-is further delin …
Unprecedented advances in our understanding of the pathobiology, prognostication, and therapeutic options in mantle cell ly
Therapeutic options for relapsed/refractory mantle cell lymphoma.
Eyre TA, Cheah CY, Wang ML. Eyre TA, et al. Blood. 2022 Feb 3;139(5):666-677. doi: 10.1182/blood.2021013326. Blood. 2022. PMID: 34679161 Free PMC article. Review.
Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma in which immunochemotherapy, with or without high-dose therapy, and autologous stem cell transplantation remain standard frontline therapies. ...We discuss the rapid recen
Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma in which immunochemotherapy, with or w
Proteasome Inhibitor Drugs.
Fricker LD. Fricker LD. Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:457-476. doi: 10.1146/annurev-pharmtox-010919-023603. Epub 2019 Sep 3. Annu Rev Pharmacol Toxicol. 2020. PMID: 31479618 Review.
Proteasome inhibitors are an important class of drugs for the treatment of multiple myeloma and mantle cell lymphoma, and they are being investigated for other diseases. Bortezomib (Velcade) was the first proteasome inhibitor to be approved by the US Food and …
Proteasome inhibitors are an important class of drugs for the treatment of multiple myeloma and mantle cell lymphoma, a …
How I manage mantle cell lymphoma: indolent versus aggressive disease.
Wilson MR, Barrett A, Cheah CY, Eyre TA. Wilson MR, et al. Br J Haematol. 2023 Apr;201(2):185-198. doi: 10.1111/bjh.18697. Epub 2023 Feb 20. Br J Haematol. 2023. PMID: 36807902 Review.
Mantle cell lymphoma (MCL) is a mature B-cell lymphoma with a variable clinical course and historically poor prognosis. ...
Mantle cell lymphoma (MCL) is a mature B-cell lymphoma with a variable clinical course and historically p
Molecular Pathogenesis of Mantle Cell Lymphoma.
Navarro A, Beà S, Jares P, Campo E. Navarro A, et al. Hematol Oncol Clin North Am. 2020 Oct;34(5):795-807. doi: 10.1016/j.hoc.2020.05.002. Epub 2020 Jul 22. Hematol Oncol Clin North Am. 2020. PMID: 32861278 Free PMC article. Review.
Mantle cell lymphoma (MCL) is a mature B-cell neoplasm with heterogeneous clinical behavior molecularly characterized by the constitutive overexpression of cyclin D1 and deregulation of different signaling pathways. ...
Mantle cell lymphoma (MCL) is a mature B-cell neoplasm with heterogeneous clinical behavior molecularly characte
Treatment approaches for patients with TP53-mutated mantle cell lymphoma.
Lew TE, Minson A, Dickinson M, Handunnetti SM, Blombery P, Khot A, Anderson MA, Ritchie D, Tam CS, Seymour JF. Lew TE, et al. Lancet Haematol. 2023 Feb;10(2):e142-e154. doi: 10.1016/S2352-3026(22)00355-6. Lancet Haematol. 2023. PMID: 36725119 Review.
Mantle cell lymphoma is an uncommon subtype of lymphoma characterised by clinical and biological heterogeneity. ...The poor outcomes for patients with TP53-mutated mantle cell lymphoma receiving chemoimmunotherapy and second-line B
Mantle cell lymphoma is an uncommon subtype of lymphoma characterised by clinical and biological heterogeneity.
Recent advances in genomics and therapeutics in mantle cell lymphoma.
Lu T, Zhang J, McCracken JM, Young KH. Lu T, et al. Cancer Treat Rev. 2024 Jan;122:102651. doi: 10.1016/j.ctrv.2023.102651. Epub 2023 Nov 4. Cancer Treat Rev. 2024. PMID: 37976759 Review.
Over the past decades, significant strides have been made in understanding the pathobiology, prognosis, and treatment options for mantle cell lymphoma (MCL). The heterogeneity observed in MCL's biology, genomics, and clinical manifestations, including indolen …
Over the past decades, significant strides have been made in understanding the pathobiology, prognosis, and treatment options for mantle
1,174 results